Abstract Number: 1277 • 2018 ACR/ARHP Annual Meeting
A Prospective Study Examining the Prevalence of CT Erosions in the Feet and Ankles of Patients with Gout Treated with Allopurinol
Background/Purpose: Gout is characterized by episodes of acute arthritis that are self-limiting. However, patients with gout can also develop tophi, bone erosions, joint deformity and…Abstract Number: 1278 • 2018 ACR/ARHP Annual Meeting
Evaluating a Causal Role of Mitochondrial Variation in the Development of Gout
Background/Purpose: Mitochondria execute roles in diverse cellular pathways. As a danger signal, damaged mitochondria can induce inflammation in response to stress through NLRP3 inflammasome activation,…Abstract Number: 1279 • 2018 ACR/ARHP Annual Meeting
Relative Insufficiency of Renal Uric Acid Excretion in Gout Patients with Obesity Leads to High Serum and Glomerular Filtration Load of Uric Acid
Background/Purpose: Gout is usually accompanied by metabolic diseases including obesity, hypertension, diabetes, and dyslipidemia. Obesity has been confirmed as a risk factor for gout. This study aims to explore…Abstract Number: 1280 • 2018 ACR/ARHP Annual Meeting
Higher Body Fat Percentage in Non-Obese Late-Onset Gout Patients
Background/Purpose: There is a trend of younger gout onset related to higher obesity prevalence. BMI is limited to discriminate between fat and lean mass. Body…Abstract Number: 1282 • 2018 ACR/ARHP Annual Meeting
Influence of Renal Function on the Velocity of Tophus Resolution and Achievement of Disease Remission in Patients with Chronic Refractory Gout Treated with Pegloticase
INFLUENCE OF RENAL FUNCTION ON THE VELOCITY OF TOPHUS RESOLUTION AND ACHEIVEMENT OF DISEASE REMISSION IN PATIENTS WITH CHRONIC REFRACTORY GOUT TREATED WITH PEGLOTICASEBackground/Purpose: Impaired…Abstract Number: 1284 • 2018 ACR/ARHP Annual Meeting
Initial Pegloticase Serum Levels Predict Persistent Responsiveness in Patients with Chronic Refractory Gout
Background/Purpose: Pegloticase is a pegylated recombinant mammalian uricase approved for treatment of persons with chronic gout refractory to standard urate lowering therapy1. Despite an initial…Abstract Number: 1285 • 2018 ACR/ARHP Annual Meeting
Comparision of Urate Burden in Well and Poorly Controlled Gout Patients: A Dual-Energy CT Study
Background/Purpose: Dual-energy computed tomography (DECT) allows sensitive and quantative detection of monosodium urate (MSU) crystals in patients with gout. Although its usefulness in diagnosing gout…Abstract Number: 1287 • 2018 ACR/ARHP Annual Meeting
Strong Impact of Dysfunctional Variants of ABCG2 on Hyperuricemia and Gout in Children and Adolescents
Background/Purpose: Common dysfunctional variants of ABCG2, a high-capacity urate transporter gene, that result in decreased urate excretion, are major causes of hyperuricemia and gout. However,…Abstract Number: 1288 • 2018 ACR/ARHP Annual Meeting
Association between Musculoskeletal Ultrasonography and Bone Remodeling Markers and the Role of Ultrasonography on Monitoring Treatment Responsiveness in Patients with Gout and Hyperuricemia
Background/Purpose: Musculoskeletal ultrasonography (US) is an invasive method to identify gout related bone damage, while Dickkopf-1 (DKK-1) and receptor activator of nuclear factor-κB ligand(RANKL)are bone…Abstract Number: 1289 • 2018 ACR/ARHP Annual Meeting
Immunosuppressant Use and Gout in the Prevalent Solid Organ Transplant Population
Background/Purpose: Gout is a frequent co-morbidity of solid organ transplant (SOT). Cyclosporine (CsA) is often cited as the main cause of gout in SOT, as…Abstract Number: 1290 • 2018 ACR/ARHP Annual Meeting
Systemic Inflammation and Atherosclerosis in Patients with Gout. Results from the NOR-Gout Study
Systemic inflammation and atherosclerosis in patients with gout. Results from the NOR-Gout studyBackground/Purpose: The association between gout and cardiovascular disease (CVD) is well known, whereas…Abstract Number: 1291 • 2018 ACR/ARHP Annual Meeting
Efficacy and Safety of Anakinra in Congestive Heart Failure Patients, Including Lvad, with Acute Gouty Arthritis: A Retrospective Study of 36 Patients at an Academic Medical Center
Background/Purpose: Gout is the most common inflammatory arthritis worldwide and many patients with gout are ‘complicated’ by multiple comorbidities including metabolic syndrome, renal disease and…Abstract Number: 1293 • 2018 ACR/ARHP Annual Meeting
Identification of New and Rare Variants in ABCG2, SLC22A1 and ALDH16A1 Genes in Crystal-Proven Early-Onset Gout
Background/Purpose: Early-onset or juvenile gout (EOG) without hypoxanthine-guanine phosphoribosyltransferase enzyme deficiency (HPRT, OMIM 300323) and not related to familial juvenile hyperuricemic nephropathy (UMOD, OMIM 300323)…Abstract Number: 1294 • 2018 ACR/ARHP Annual Meeting
Initial Phase 2 Clinical Data of SEL-212 in Symptomatic Gout Patients: Monthly Dosing of a Pegylated Uricase (Pegadricase) with Svp-Rapamycin Enables Sustained Reduction of Acute Gout Flares
Background/Purpose: Pegylated uricases are therapies for treatment of severe chronic gout, particularly for rapid tophi resolution. However, uricases are limited by induction of anti-drug antibodies…Abstract Number: 1297 • 2018 ACR/ARHP Annual Meeting
Risk of Dementia in Patients with Gout and the Impact of Urate-Lowering Therapies: A Large Population-Based Cohort Study
Background/Purpose: Evidence is conflicting concerning dementia risk in gout patients, with hyperuricaemia proposed to exert a neuroprotective effect. Serum urate (sUA) targets guiding urate-lowering therapies…
Simple Search Results
Didn't find what you were looking for? Try the Advanced Search »
Didn't find what you were looking for? Try the Advanced Search »